Abstract
Background: Carnitine-acylcarnitine translocase (CACT) deficiency is a rare autosomal recessive disease in the mitochondrial transport of long-chain fatty acids. Despite early diagnosis and treatment, the disease still has a high mortality rate.
Methods: Clinical symptoms, long-term follow-up, and biochemical and molecular results of four cases are described and compared with the reviewed literature data of 55 cases.
Results: Two cases with neonatal onset, carrying in homozygosity the novel variant sequences p.Gly20Asp (c.59G>A) and p.Arg179Gly (c.536A>G), died during an intercurrent infectious process in the first year of life despite adequate dietetic treatment (frequent feeding, high-carbohydrate/low-fat diet, MCT, carnitine). The other two cases, one with infantile onset and the other diagnosed in the newborn period after a previous affected sibling, show excellent development at 4 and 16 years of age under treatment. The review shows that the most frequent presenting symptoms of CACT deficiency are hypoketotic hypoglycemia, hyperammonemia, hepatomegaly, cardiomyopathy and/or arrhythmia, and respiratory distress. The onset of symptoms is predominantly neonatal in 82% and infantile in 18%. The mortality rate is high (65%), most in the first year of life due to myocardiopathy or sudden death. Outcomes seem to correlate better with the absence of cardiac disease and with a higher long-chain fatty acid oxidation rate in cultured fibroblasts than with residual enzyme activity.
Conclusion: Diagnosis before the occurrence of clinical symptoms by tandem MS–MS and very early therapeutic intervention together with good dietary compliance could lead to a better prognosis, especially in milder clinical cases.
Competing interests: None declared
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Al Aqeel AI, Rashid MS, Ruiter JP, Ijlst L, Wanders RJ (2003) A novel molecular defect of the carnitine acylcarnitine translocase gene in a Saudi patient. Clin Genet 64:163–165
Al-Sannaa NA, Cheriyan GM (2010) Carnitine-acylcarnitine translocase deficiency. Clinical course of three Saudi children with a severe phenotype. Saudi Med J 31:931–934
Baruteau J, Sachs P, Broue P et al (2013) Clinical and biological features at diagnosis in mitochondrial fatty acid beta-oxidation defects: a French pediatric study from 187 patients. Complementary data. J Inherit Metab Dis 37:137–139
Bonnefont JP, Bastin J, Behin A, Djouadi F (2009) Bezafibrate for an inborn mitochondrial beta-oxidation defect. N Engl J Med 360:838–840
Brivet M (2004) Carnitine-acylcarnitine translocase deficiency. Orphanet Encyclopedia 1–5
Brivet M, Slama A, Millington DS et al (1996) Retrospective diagnosis of carnitine-acylcarnitine translocase deficiency by acylcarnitine analysis in the proband Guthrie card and enzymatic studies in the parents. J Inherit Metab Dis 19:181–184
Chalmers RA, Stanley CA, English N, Wigglesworth JS (1997) Mitochondrial carnitine-acylcarnitine translocase deficiency presenting as sudden neonatal death. J Pediatr 131:220–225
Chien YH, Lee NC, Chao MC et al (2013) Fatty Acid oxidation disorders in a chinese population in taiwan. JIMD Rep 11:165–172
Costa C, Costa JM, Nuoffer JM et al (1999) Identification of the molecular defect in a severe case of carnitine-acylcarnitine carrier deficiency. J Inherit Metab Dis 22:267–270
Costa C, Costa JM, Slama A et al (2003) Mutational spectrum and DNA-based prenatal diagnosis in carnitine-acylcarnitine translocase deficiency. Mol Genet Metab 78:68–73
Djouadi F, Bonnefont JP, Thuillier L et al (2003) Correction of fatty acid oxidation in carnitine palmitoyl transferase 2-deficient cultured skin fibroblasts by bezafibrate. Pediatr Res 54:446–451
Fearing MK, Israel EJ, Sahai I, Rapalino O, Lisovsky M (2011) Case records of the Massachusetts General Hospital. Case 12–2011. A 9-month-old boy with acute liver failure. N Engl J Med 364:1545–1556
Fukushima T, Kaneoka H, Yasuno T et al (2013) Three novel mutations in the carnitine-acylcarnitine translocase (CACT) gene in patients with CACT deficiency and in healthy individuals. J Hum Genet 58:788–793
Galron D, Birk OS, Kazanovitz A, Moses SW, Hershkovitz E (2004) Carnitine-acylcarnitine translocase deficiency: identification of a novel molecular defect in a Bedouin patient. J Inherit Metab Dis 27:267–273
Geven WB, Niezen-Koning KE, Timmer A, van Loon AJ, Wanders RJ, van Spronsen FJ (2007) Pre-eclampsia in a woman whose child suffered from lethal carnitine-acylcarnitine translocase deficiency. BJOG 114:1028–1030
Gobin-Limballe S, Djouadi F, Aubey F et al (2007) Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapy. Am J Hum Genet 81:1133–1143
Haberle J (2013) Clinical and biochemical aspects of primary and secondary hyperammonemic disorders. Arch Biochem Biophys 536:101–108
Hsu BY, Iacobazzi V, Wang Z, Harvie H, Chalmers RA, Saudubray JM, Palmieri F, Ganguly A, Stanley CA (2001) Aberrant mRNA splicing associated with coding region mutations in children with carnitine-acylcarnitine translocase deficiency. Mol Genet Metab 74:248–255
Huizing M, Iacobazzi V, Ijlst L et al (1997) Cloning of the human carnitine-acylcarnitine carrier cDNA and identification of the molecular defect in a patient. Am J Hum Genet 61:1239–1245
Huizing M, Wendel U, Ruitenbeek W et al (1998) Carnitine-acylcarnitine carrier deficiency: identification of the molecular defect in a patient. J Inherit Metab Dis 21:262–267
Iacobazzi V, Invernizzi F, Baratta S et al (2004a) Molecular and functional analysis of SLC25A20 mutations causing carnitine-acylcarnitine translocase deficiency. Hum Mutat 24:312–320
Iacobazzi V, Pasquali M, Singh R et al (2004b) Response to therapy in carnitine/acylcarnitine translocase (CACT) deficiency due to a novel missense mutation. Am J Med Genet A 126A:150–155
Iacobazzi V, Convertini P, Infantino V, Scarcia P, Todisco S, Palmieri F (2009) Statins, fibrates and retinoic acid upregulate mitochondrial acylcarnitine carrier gene expression. Biochem Biophys Res Commun 388:643–647
Ijlst L, van Roermund CW, Iacobazzi V, Oostheim W, Ruiter JP, Williams JC, Palmieri F, Wanders RJ (2001) Functional analysis of mutant human carnitine acylcarnitine translocases in yeast. Biochem Biophys Res Commun 280:700–706
Indiveri C, Iacobazzi V, Tonazzi A et al (2011) The mitochondrial carnitine/acylcarnitine carrier: function, structure and physiopathology. Mol Aspects Med 32:223–233
Korman SH, Pitt JJ, Boneh A et al (2006) A novel SLC25A20 splicing mutation in patients of different ethnic origin with neonatally lethal carnitine-acylcarnitine translocase (CACT) deficiency. Mol Genet Metab 89:332–338
Lee RS, Lam CW, Lai CK et al (2007) Carnitine-acylcarnitine translocase deficiency in three neonates presenting with rapid deterioration and cardiac arrest. Hong Kong Med J 13:66–68
Lopriore E, Gemke RJ, Verhoeven NM et al (2001) Carnitine-acylcarnitine translocase deficiency: phenotype, residual enzyme activity and outcome. Eur J Pediatr 160:101–104
Lund AM, Skovby F, Vestergaard H, Christensen M, Christensen E (2010) Clinical and biochemical monitoring of patients with fatty acid oxidation disorders. J Inherit Metab Dis 33:495–500
Morris AA, Olpin SE, Brivet M, Turnbull DM, Jones RA, Leonard JV (1998) A patient with carnitine-acylcarnitine translocase deficiency with a mild phenotype. J Pediatr 132:514–516
Niezen-Koning KE, van Spronsen FJ, Ijlst L et al (1995) A patient with lethal cardiomyopathy and a carnitine-acylcarnitine translocase deficiency. J Inherit Metab Dis 18:230–232
Nuoffer JM, de Lonlay P, Costa C et al (2000) Familial neonatal SIDS revealing carnitine-acylcarnitine translocase deficiency. Eur J Pediatr 159:82–85
Ogawa A, Yamamoto S, Kanazawa M, Takayanagi M, Hasegawa S, Kohno Y (2000) Identification of two novel mutations of the carnitine/acylcarnitine translocase (CACT) gene in a patient with CACT deficiency. J Hum Genet 45:52–55
Ogier de Baulny H, Slama A, Touati G, Turnbull DM, Pourfarzam M, Brivet M (1995) Neonatal hyperammonemia caused by a defect of carnitine-acylcarnitine translocase. J Pediatr 127:723–728
Olpin SE, Bonham JR, Downing M et al (1997) Carnitine-acylcarnitine translocase deficiency–a mild phenotype. J Inherit Metab Dis 20:714–715
Palmieri F (2008) Diseases caused by defects of mitochondrial carriers: a review. Biochim Biophys Acta 1777:564–578
Pande SV, Brivet M, Slama A, Demaugre F, Aufrant C, Saudubray JM (1993) Carnitine-acylcarnitine translocase deficiency with severe hypoglycemia and auriculo ventricular block. Translocase assay in permeabilized fibroblasts. J Clin Invest 91:1247–1252
Parini R, Invernizzi F, Menni F et al (1999) Medium-chain triglyceride loading test in carnitine-acylcarnitine translocase deficiency: insights on treatment. J Inherit Metab Dis 22:733–739
Pierre G, Macdonald A, Gray G, Hendriksz C, Preece MA, Chakrapani A (2007) Prospective treatment in carnitine-acylcarnitine translocase deficiency. J Inherit Metab Dis 30:815
Roe CR, Mochel F (2006) Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential. J Inherit Metab Dis 29:332–340
Roschinger W, Muntau AC, Duran M et al (2000) Carnitine-acylcarnitine translocase deficiency: metabolic consequences of an impaired mitochondrial carnitine cycle. Clin Chim Acta 298:55–68
Rubio-Gozalbo ME, Vos P, Forget PP et al (2003) Carnitine-acylcarnitine translocase deficiency: case report and review of the literature. Acta Paediatr 92:501–504
Rubio-Gozalbo ME, Bakker JA, Waterham HR, Wanders RJ (2004) Carnitine-acylcarnitine translocase deficiency, clinical, biochemical and genetic aspects. Mol Aspects Med 25:521–532
Spiekerkoetter U, Duran M (2014) Mitochondrial fatty acid oxidation defects. In: Blau N, Duran M, Gibson KM, Dionisi-Visi C (eds) Physician’s guide to the diagnosis, treatment, and follow-up of inherited metabolic diseases. Springer-Verlag, Berlin/Heidelberg, pp 247–264
Spiekerkoetter U, Lindner M, Santer R et al (2009) Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. J Inherit Metab Dis 32:498–505
Stanley CA, Hale DE, Berry GT, Deleeuw S, Boxer J, Bonnefont JP (1992) Brief report: a deficiency of carnitine-acylcarnitine translocase in the inner mitochondrial membrane. N Engl J Med 327:19–23
Wang GL, Wang J, Douglas G et al (2011) Expanded molecular features of carnitine acyl-carnitine translocase (CACT) deficiency by comprehensive molecular analysis. Mol Genet Metab 103:349–357
Yang BZ, Mallory JM, Roe DS et al (2001) Carnitine/acylcarnitine translocase deficiency (neonatal phenotype): successful prenatal and postmortem diagnosis associated with a novel mutation in a single family. Mol Genet Metab 73:64–70
Acknowledgments
The authors would like to thank the families for giving their consent. We are grateful to Dr. Nerea Gorria from Hospital General Yagüe in Burgos for supplying the first clinical data from case 3. We gratefully acknowledge the funding by Mitolab (S2010/BMD-2402) DGUI Comunidad de Madrid.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Communicated by: Gregory Enns
Appendices
Take-Home Message
Long-term clinical outcome in carnitine-acylcarnitine translocase deficiency seems to be better in those cases with a very early therapeutic intervention and a good dietary compliance with diet.
Compliance with Ethics Guidelines
Conflict of Interest
I Vitoria, E Martín-Hernández, L Peña-Quintana, M Bueno, P Quijada-Fraile, J Dalmau, S Molina-Marrero, B Pérez, and B Merinero declare that they have no conflict of interest.
Informed Consent
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study.
Details of the Contributions of Individual Authors
IV: clinical data of case 1, conception and design, drafting, and coordination of the manuscript
EM-H: clinical data of case 3, analysis of the data, and critical reading of the manuscript
LP-Q: clinical data of case 2, analysis of the data, and critical reading of the manuscript
MB: clinical care of case 4 and critical reading of the manuscript
PQF: critical reading of the manuscript
JD: clinical data of case 1 and critical reading of the manuscript
SM-M: clinical data of case 2 and critical reading of the manuscript
BP: molecular genetic analysis and interpretation of cases 1, 2, and 3
BM: biochemical diagnosis and interpretation of cases 1, 2, and 3, conception and design, and drafting of the manuscript
Rights and permissions
Copyright information
© 2014 SSIEM and Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Vitoria, I. et al. (2014). Carnitine-Acylcarnitine Translocase Deficiency: Experience with Four Cases in Spain and Review of the Literature. In: Zschocke, J., Baumgartner, M., Morava, E., Patterson, M., Rahman, S., Peters, V. (eds) JIMD Reports, Volume 20. JIMD Reports, vol 20. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2014_382
Download citation
DOI: https://doi.org/10.1007/8904_2014_382
Received:
Revised:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-46699-5
Online ISBN: 978-3-662-46700-8
eBook Packages: MedicineMedicine (R0)